<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749514</url>
  </required_header>
  <id_info>
    <org_study_id>A536-03</org_study_id>
    <nct_id>NCT01749514</nct_id>
  </id_info>
  <brief_title>Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)</brief_title>
  <official_title>A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of ACE-536 on anemia in patients with&#xD;
      low or intermediate-1 risk MDS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who have a modified erythroid response (mHI-E).</measure>
    <time_frame>Assessed at approximately 28 weeks from patient screening.</time_frame>
    <description>mHI-E defined as a hemoglobin increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of red blood cell [RBC] transfusions) in non-transfusion dependent patients, or, a reduction of either ≥ 4 units or ≥ 50% of units of RBCs transfused compared to pre treatment in transfusion dependent patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of ACE-536, as determined by the number of patients with adverse events.</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of erythroid, neutrophil and platelet (HI-E, HI-N and HI-P) responses.</measure>
    <time_frame>Measured during any 8 week period on study, up to 28 weeks from patient screening, compared with the 8-week period prior to study day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mHI-E response and HI-E response and duration of mHI-E and HI-E response.</measure>
    <time_frame>Measured over the course of study, up to approximately 24 weeks from initiation of dosing on study day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of RBC transfusions in transfusion-dependent patients.</measure>
    <time_frame>Approximately 28 weeks from patient screening.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACE-536 serum half-life (T1/2)</measure>
    <time_frame>Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACE-536 peak serum concentration (Cmax)</measure>
    <time_frame>Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak serum concentration of ACE-536 (Tmax)</measure>
    <time_frame>Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACE-536 exposure (Area Under the serum Concentration Curve, AUC0-t)</measure>
    <time_frame>Measured at multiple time points over the course of treatment, from study day 1 to approximately 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of total serum iron concentration (ug/dL)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Total Iron Binding Capacity (ug/dL)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of soluble transferrin receptor (ug/mL)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of serum ferritin (ng/mL)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of non-transferrin bound iron (umoles/L)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of serum hepcidin (ng/mL)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of serum erythropoietin concentration (mU/mL)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte count (%)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of serum levels of bone-specific alkaline phosphatase (ug/L)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of serum levels of cross-linked C-telopeptide of type I collagen (ng/L)</measure>
    <time_frame>From treatment initiation to End-of-Study visit (approximately 28 weeks later)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>ACE-536</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to 1 of 7 possible dosing groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-536</intervention_name>
    <description>Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.</description>
    <arm_group_label>ACE-536</arm_group_label>
    <other_name>luspatercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of idiopathic/de novo MDS or non-proliferative chronic&#xD;
             myelomonocytic leukemia (CMML), according to WHO criteria (white blood count,&#xD;
             13,000/uL), that meets International Prognostic Scoring System (IPSS) classification&#xD;
             of low or intermediate-1 risk disease as determined by microscopic and standard&#xD;
             cytogenetic analyses of the bone marrow and peripheral complete blood count (CBC)&#xD;
             obtained during screening.&#xD;
&#xD;
          2. Anemia defined as:&#xD;
&#xD;
               1. Mean hemoglobin concentration &lt; 10.0 g/dL of 2 measurements (one performed within&#xD;
                  one day prior to Cycle 1 Day 1 and the other performed 7-28 days prior to Cycle 1&#xD;
                  Day 1, not influenced by RBC transfusion within 7 days of measurement) for&#xD;
                  non-transfusion dependent patients (defined as having received &lt; 4 units of RBCs&#xD;
                  within 8 weeks prior to Cycle 1 Day 1), OR&#xD;
&#xD;
               2. Transfusion dependent, defined as having received ≥ 4 units of RBCs within 8&#xD;
                  weeks prior to Cycle 1 Day 1.&#xD;
&#xD;
          3. Serum erythropoietin levels and prior erythropoiesis-stimulating agent (ESA)&#xD;
             treatment:&#xD;
&#xD;
               -  Dose escalation cohorts and expansion cohort 1 patients: Serum erythropoietin&#xD;
                  level &gt; 500 U/L, OR, if ≤ 500 U/L, patient is non-responsive, refractory, or&#xD;
                  intolerant to erythropoiesis-stimulating agents (ESAs), or ESAs are&#xD;
                  contraindicated or unavailable.&#xD;
&#xD;
               -  Expansion cohort 2 patients: If patient is RS+ (defined as having ≥ 15% ring&#xD;
                  sideroblasts in the bone marrow), no prior ESA treatment and serum erythropoietin&#xD;
                  level ≤ 200 U/L. If a patient is RS- (defined as having &lt; 15% ring sideroblasts&#xD;
                  in the bone marrow), prior ESA treatment and any serum erythropoietin level is&#xD;
                  allowed.&#xD;
&#xD;
          4. No alternative treatment options, per applicable MDS guidelines, are available and/or&#xD;
             appropriate for the patient, at the discretion of the investigator.&#xD;
&#xD;
          5. ECOG performance status of 0, 1, or 2 (if related to anemia).&#xD;
&#xD;
          6. Adequate renal (creatinine ≤ 2 x upper limit of normal [ULN]) and hepatic (total&#xD;
             bilirubin &lt; 2 x ULN and AST and ALT &lt; 3 x ULN) function.&#xD;
&#xD;
          7. Adequate transferrin saturation (≥ 15%), ferritin (≥ 50 µg/L), folate (≥ 4.5 nmol/L [≥&#xD;
             2.0 µg/L]) and vitamin B12 (≥ 148 pmol/L [≥ 200 pg/mL]) during screening&#xD;
             (supplementation and retest during screening is acceptable).&#xD;
&#xD;
          8. Females of child bearing potential (defined as sexually mature women who have not&#xD;
             undergone hysterectomy or bilateral oophorectomy, or are not naturally postmenopausal&#xD;
             ≥ 24 consecutive months) must have negative urine or blood pregnancy test prior to&#xD;
             enrollment and use adequate birth control methods (abstinence, oral contraceptives,&#xD;
             barrier method with spermicide, or surgical sterilization) during study participation&#xD;
             and for 12 weeks following the last dose of ACE-536. Males must agree to use a latex&#xD;
             condom during any sexual contact with females of child-bearing potential while&#xD;
             participating in the study and for 12 weeks following the last dose of ACE 536, even&#xD;
             if he has undergone a successful vasectomy. Patients must be counseled concerning&#xD;
             measures to be used to prevent pregnancy and potential toxicities prior to the first&#xD;
             dose of ACE-536.&#xD;
&#xD;
          9. Patients are able to adhere to the study visit schedule, understand and comply with&#xD;
             all protocol requirements.&#xD;
&#xD;
         10. Patients understand and are able to provide written informed consent.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with azacitidine or decitabine.&#xD;
&#xD;
          2. Treatment within 28 days prior to Cycle 1 Day 1 with:&#xD;
&#xD;
             i) Erythropoiesis stimulating agent (ESA), ii) Granulocyte colony-stimulating factor&#xD;
             (G-CSF) and granulocyte- macrophage colony stimulating factor (GM-CSF), iii)&#xD;
             Lenalidomide.&#xD;
&#xD;
          3. Iron chelation therapy if initiated within 56 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          4. Treatment with another investigational drug or device, or approved therapy for&#xD;
             investigational use ≤ 28 days prior to Cycle 1 Day 1, or if the half-life of the&#xD;
             previous product is known, within 5 times the half-life prior to Cycle 1 Day 1,&#xD;
             whichever is longer.&#xD;
&#xD;
          5. Major surgery within 28 days prior to Cycle 1 Day 1. Patients must have completely&#xD;
             recovered from any previous surgery prior to Cycle 1 Day 1.&#xD;
&#xD;
          6. Platelet count &lt; 30 x 109/L.&#xD;
&#xD;
          7. Any active infection requiring parenteral antibiotic therapy within 28 days prior to&#xD;
             Cycle 1 Day 1 or oral antibiotics within 14 days of Cycle 1 Day 1.&#xD;
&#xD;
          8. History of stroke, deep venous thrombosis (DVT) or arterial embolism within 6 months&#xD;
             prior to Cycle 1 Day 1.&#xD;
&#xD;
          9. Known positive for human immunodeficiency virus (HIV), active infectious hepatitis B&#xD;
             (HBV) or active infectious hepatitis C (HCV).&#xD;
&#xD;
         10. Any malignancy other than MDS which has not been in remission and/or has required&#xD;
             systemic therapy including radiation, chemotherapy, hormonal therapy or surgery,&#xD;
             within the last year prior to Cycle 1 Day 1.&#xD;
&#xD;
         11. Uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 150 mm Hg or&#xD;
             diastolic BP ≥ 100 mm Hg.&#xD;
&#xD;
         12. Pregnant or lactating females.&#xD;
&#xD;
         13. History of severe allergic or anaphylactic reactions or hypersensitivity to&#xD;
             recombinant proteins or excipients in the investigational drug.&#xD;
&#xD;
         14. Any other condition not specifically noted above which, in the judgment of the&#xD;
             investigator, would preclude the patient from participating in the study.&#xD;
&#xD;
         15. Transfusion event within 7 days prior to Cycle 1 Day 1.&#xD;
&#xD;
         16. Prior treatment with sotatercept (ACE-011) or ACE-536.&#xD;
&#xD;
         17. Secondary MDS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Acceleron Investigative Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002523-14/results</url>
    <description>A536-03 Protocol EudraCT 2012-002523-14 Results Posting</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Luspatercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

